Enable Injections

Enable Injections is a private, commercial-stage medical device company focused on redefining drug delivery for biologics and other high-volume therapies. Its flagship enFuse® wearable platform allows for the subcutaneous administration of large-volume drugs, offering patients greater freedom and convenience compared to traditional IV administration. The company has established key partnerships with pharmaceutical firms like Incyte and Sanofi, has a commercially approved product for Empaveli, and is actively expanding its manufacturing and global regulatory footprint. Enable operates at the intersection of drug delivery and biologics, providing a platform technology to pharmaceutical partners.

The enFuse® On-Body Platform is a wearable drug delivery system designed for the subcutaneous administration of large-volume medications. It includes the wearable injector, drug-specific transfer systems, and smart technology for connectivity and data tracking.

Enable Injections competes in the wearable large-volume injector market against established device companies like West Pharmaceutical Services (with its SmartDose® technology) and Ypsomed (with its YpsoMate®). Competition is based on device ergonomics, volume capacity, ease of use, and the strength of pharma partnerships.